Indivior PLC (INDV) - Total Liabilities

Latest as of June 2025: GBX1.71 Billion GBX ≈ $208.06K USD

Based on the latest financial reports, Indivior PLC (INDV) has total liabilities worth GBX1.71 Billion GBX (≈ $208.06K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Indivior PLC (INDV) cash conversion ratio to assess how effectively this company generates cash.

Indivior PLC - Total Liabilities Trend (2011–2024)

This chart illustrates how Indivior PLC's total liabilities have evolved over time, based on quarterly financial data. Check INDV asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Indivior PLC Competitors by Total Liabilities

The table below lists competitors of Indivior PLC ranked by their total liabilities.

Company Country Total Liabilities
Lipidor Ab
ST:LIPI
Sweden Skr3.86 Million
Higher Way Electronic Co Ltd
TWO:3268
Taiwan NT$548.21 Million
Tuju Setia Bhd
KLSE:5297
Malaysia RM447.21 Million
Smithson Investment Trust PLC
LSE:SSON
UK GBX1.63 Million
NanoRepro AG
XETRA:NN6
Germany €694.21K
Naos Ex-50 Opportunities Company Ltd
AU:NAC
Australia AU$18.30 Million
Overactive Media Corp
V:OAM
Canada CA$21.11 Million
Century Extrusions Limited
NSE:CENTEXT
India Rs933.40 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Indivior PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see INDV market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.90 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -6.63 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.18 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Indivior PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Indivior PLC (2011–2024)

The table below shows the annual total liabilities of Indivior PLC from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 GBX1.67 Billion
≈ $202.83K
-15.17%
2023-12-31 GBX1.97 Billion
≈ $239.08K
+14.38%
2022-12-31 GBX1.72 Billion
≈ $209.03K
+5.46%
2021-12-31 GBX1.63 Billion
≈ $198.20K
+12.42%
2020-12-31 GBX1.45 Billion
≈ $176.30K
+0.42%
2019-12-31 GBX1.44 Billion
≈ $175.57K
-2.57%
2018-12-31 GBX1.48 Billion
≈ $180.19K
-10.08%
2017-12-31 GBX1.65 Billion
≈ $200.39K
+9.51%
2016-12-31 GBX1.50 Billion
≈ $182.99K
+23.68%
2015-12-31 GBX1.22 Billion
≈ $147.95K
-0.49%
2014-12-31 GBX1.22 Billion
≈ $148.68K
+148.37%
2013-12-31 GBX492.00 Million
≈ $59.86K
+19.42%
2012-12-31 GBX412.00 Million
≈ $50.13K
+35.08%
2011-12-31 GBX305.00 Million
≈ $37.11K
--

About Indivior PLC

LSE:INDV UK Drug Manufacturers - Specialty & Generic
Market Cap
$18.79 Million
GBX154.47 Billion GBX
Market Cap Rank
#25230 Global
#257 in UK
Share Price
GBX1238.00
Change (1 day)
+1.56%
52-Week Range
GBX825.50 - GBX1238.00
All Time High
GBX2481.00
About

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more